The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease

by NASDAQ Market News November 18, 2021

NASDAQ Market News
Click here to email author

Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Teleflex Earns Top Spot in MedReps Best Places to Work 2022 Ranking

Ads